Citadel Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-3,500
| Closed | -$52.3K | – | 16250 |
|
|
2022
Q4 | $52.3K | Buy |
+3,500
| New | +$48.5K | ﹤0.01% | 12073 |
|
|
2022
Q2 | – | Sell |
-11,900
| Closed | -$67K | – | 14909 |
|
|
2022
Q1 | $67K | Sell |
11,900
-5,700
| -32% | -$23.5K | ﹤0.01% | 12611 |
|
|
2021
Q4 | $83K | Sell |
17,600
-6,800
| -28% | -$42.2K | ﹤0.01% | 12915 |
|
|
2021
Q3 | $151K | Sell |
24,400
-6,900
| -22% | -$41.3K | ﹤0.01% | 12377 |
|
|
2021
Q2 | $206K | Sell |
31,300
-49,500
| -61% | -$341K | ﹤0.01% | 12099 |
|
|
2021
Q1 | $591K | Buy |
80,800
+47,540
| +143% | +$410K | ﹤0.01% | 9321 |
|
|
2020
Q4 | $192K | Buy |
33,260
+5,460
| +20% | +$31.3K | ﹤0.01% | 9769 |
|
|
2020
Q3 | $165K | Buy |
27,800
+16,300
| +142% | +$80.6K | ﹤0.01% | 8949 |
|
|
2020
Q2 | $59K | Buy |
+11,500
| New | +$72.6K | ﹤0.01% | 9236 |
|
|
2020
Q1 | – | Sell |
-21,430
| Closed | -$134K | – | 10559 |
|
|
2019
Q4 | $134K | Buy |
21,430
+2,040
| +11% | +$15K | ﹤0.01% | 8420 |
|
|
2019
Q3 | $164K | Buy |
19,390
+13,320
| +219% | +$99.1K | ﹤0.01% | 8257 |
|
|
2019
Q2 | $41K | Sell |
6,070
-4,950
| -45% | -$42.4K | ﹤0.01% | 8794 |
|
|
2019
Q1 | $90K | Sell |
11,020
-6,340
| -37% | -$65.5K | ﹤0.01% | 8596 |
|
|
2018
Q4 | $278K | Sell |
17,360
-1,050
| -6% | -$23.1K | ﹤0.01% | 7405 |
|
|
2018
Q3 | $609K | Buy |
18,410
+10,640
| +137% | +$273K | ﹤0.01% | 6380 |
|
|
2018
Q2 | $176K | Buy |
7,770
+5,600
| +258% | +$133K | ﹤0.01% | 7984 |
|
|
2018
Q1 | $63K | Buy |
+2,170
| New | +$63.5K | ﹤0.01% | 7859 |
|
|
2016
Q1 | – | Sell |
-1,320
| Closed | -$17K | – | 8540 |
|
|
2015
Q4 | $17K | Sell |
1,320
-270
| -17% | -$3.21K | ﹤0.01% | 8053 |
|
|
2015
Q3 | $19K | Sell |
1,590
-910
| -36% | -$13.2K | ﹤0.01% | 8209 |
|
|
2015
Q2 | $44K | Buy |
+2,500
| New | +$45K | ﹤0.01% | 7747 |
|
|
2014
Q4 | – | Sell |
-270
| Closed | -$3K | – | 8853 |
|
|
2014
Q3 | $3K | Buy |
+270
| New | +$3.43K | ﹤0.01% | 7975 |
|
Citadel Advisors's AVEO Position: Q1 2023 in Review
Citadel Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 315,477 shares — an estimated $4.72M sold.
Citadel Advisors first reported a position in AVEO in Q2 2013 and held it in 25 quarters. The position peaked at $4.72M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Citadel Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 315,477 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $4.72M.
- Citadel Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 25 quarters.
- Citadel Advisors's AVEO Pharmaceuticals, Inc. position peaked at $4.72M in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.